Federico Longo-Muñoz

Author

Hospital Universitario Ramón y Cajal

Also Known As

F Longo-Muñoz, F. Longo-Muñoz, Federico Longo-Munoz, Federico Longo-Muñoz, Stefania Beghelli

Publications

283

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Ramón y Cajal Centro de Investigación Biomédica en Red de Cáncer Instituto de Salud Carlos III Instituto Ramón y Cajal de Investigación Sanitaria Hospital Universitario Virgen del Rocío

About

Federico Longo-Muñoz is an author at Hospital Universitario Ramón y Cajal.

Federico Longo-Muñoz

Publications

282

Citations

H-Index

Page 1

	Year	Citations
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer Eric Van Cutsem, R. Mayer, Stéphanie Laurent, European Journal of Cancer	2017	94
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) Alfredo Carrato, Albert Abad, Bartomeu Massutí, European Journal of Cancer	2017	87
Does Rapid Drug Desensitization to Chemotherapy Affect Survival Outcomes? MP Berges-Gimeno, LV Carpio-Escalona, Federico Longo-Muñoz, Journal of Investigational Allergology and Clinical Immunology	2019	34
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial Federico Longo-Muñoz, Guillem Argilés, Josep Tabernero, Clinical & Translational Oncology	2016	32
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors Édouard Auclin, Perrine Vuagnat, Cristina Smolenschi, Cancers	2021	14
Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study Pilar García‐Alfonso, Andrés J. Muñoz Martín, Jerónimo Jiménez-Castro, Cancers	2021	11
Abstract P3-09-19: Preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer J. Randolph Hecht, Arlene Chan, Jean‐François Baurain, Cancer Research	2020	10

Page 1